Inmed announces publication of study on anti-inflammation by modulation of endocannabinoid system

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application vancouver, british columbia--(newsfile corp. - november 19, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that a peer-reviewed scientific study entitled "cannabinol modulates the endocannabinoid system and shows trpv1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal biofactors. this company-sponsored study demonstrates the biological activity of cannabinol ("cbn") and its potential anti-inflammatory effects in skin diseases.
INM Ratings Summary
INM Quant Ranking